Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Depreciation & Amortization (CF) of $55.9 million for Q1 2026, up 15.5% year-over-year from $48.4 million in Q1 2025, and little changed quarter-over-quarter from $55.7 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $55.9 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 15.5% year-over-year to $55.9 million; the TTM figure through Mar 2026 stood at $217.3 million (up 7.52% YoY), while the FY2025 annual figure was $209.8 million, up 1.25% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $55.9 million, roughly flat from $55.7 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $59.0 million in Q4 2023, with the low at $35.9 million in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $48.4 million (2025), against an average of $47.2 million.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) surged 53.65% in 2023, then fell 21.19% in 2024.
- Vertex Pharmaceuticals' Depreciation & Amortization (CF) stood at $38.4 million in 2022, then soared by 53.65% to $59.0 million in 2023, then dropped by 21.19% to $46.5 million in 2024, then increased by 19.78% to $55.7 million in 2025, then gained by 0.36% to $55.9 million in 2026.
- Business Quant data shows VRTX's Depreciation & Amortization (CF) at $55.9 million in Q1 2026, $55.7 million in Q4 2025, and $54.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 600,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.50 Mn |
| Jun 30, 2026 | 56.50 Mn |
| Mar 31, 2026 | 55.90 Mn |
| Mar 31, 2026 | 55.90 Mn |
| Dec 31, 2025 | 55.70 Mn |
| Dec 31, 2025 | 55.70 Mn |
| Sep 30, 2025 | 54.00 Mn |
| Sep 30, 2025 | 54.00 Mn |
| Jun 30, 2025 | 51.70 Mn |
| Jun 30, 2025 | 51.70 Mn |
| Mar 31, 2025 | 48.40 Mn |
| Mar 31, 2025 | 48.40 Mn |
| Dec 31, 2024 | 46.50 Mn |
| Dec 31, 2024 | 46.50 Mn |
| Sep 30, 2024 | 53.20 Mn |
| Sep 30, 2024 | 53.20 Mn |
| Jun 30, 2024 | 54.00 Mn |
| Jun 30, 2024 | 54.00 Mn |
| Mar 31, 2024 | 53.50 Mn |
| Mar 31, 2024 | 53.50 Mn |